Recreational use of nitrous oxide (NO) has increased rapidly in recent years and is now the second most commonly used recreational drug among young people in the UK. There has been a corresponding rise in cases of nitrous oxide-induced subacute combined degeneration of the cord (NO-SACD), a pattern of myeloneuropathy usually associated with severe vitamin B deficiency. This can cause serious and permanent disability in young people but, if recognised early, may be effectively treated. All neurologists should be aware of NO-SACD and its treatment; however, there are currently no agreed guidelines. Based on our experience in East London, an area of high NO use, we provide practical advice on its recognition, investigation and treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313972 | PMC |
| http://dx.doi.org/10.1136/pn-2022-003631 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nitrous Oxide-Induced Vitamin B12 Deficiency and Myelopathy in Whippets Abusers: A Report of Two Cases.
Cureus
November 2024
Neurology, Marshall University Joan C. Edwards School of Medicine, Huntington, USA.
Whippets abuse, prevalent among recreational drug users, poses significant health risks, particularly through the inactivation of vitamin B12 by nitrous oxide (NO). This deficiency can lead to myelopathy, resulting in serious neurological complications. We present two female patients, aged 22 and 35, with a history of regular whippet use over the past three years, who exhibited clinical symptoms of myelopathy, including motor weakness, rigidity, sensory changes, and gait abnormalities.
View Article and Find Full Text PDFNitrous oxide abuse and associated neurological diseases.
BMC Neurol
November 2024
Chulabhorn International College of Medicine, Thammasat University, Bangkok, Thailand.
Article Synopsis
- Nitrous oxide, commonly used as an anesthetic, is increasingly abused recreationally, leading to neurological issues in users.
- A study reviewed seven patients aged 19-32 who inhaled nitrous oxide and subsequently experienced ataxia and sensory dysfunction, with some showing coexisting encephalopathy.
- Although patients had poor short-term outcomes, most showed significant recovery after more than six months, indicating potential long-term improvement despite initial symptoms.
Mechanisms and recent advances in the diagnosis and treatment of nitrous oxide-induced peripheral neuropathy: a narrative review.
Front Neurol
May 2024
Department of Orthopedics, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Under standard conditions, nitrous oxide (NO) manifests as a colorless, odorless gas with a mildly sweet taste. The compound finds applications in various fields, including its use as an aerosol propellants, an accelerant in motor racing, and an anesthetic in surgical procedures and dentistry. Unfortunately, the recreational misuse of NO has become prevalent among young individuals due to its euphoric and hallucinogenic effects.
View Article and Find Full Text PDFEvaluation of an ambulatory care pathway for patients with nitrous oxide-induced myeloneuropathy.
BMJ Neurol Open
June 2024
Centre for Preventive Neurology, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.
Introduction: Cases of nitrous oxide (NO)-induced myeloneuropathy are increasing at UK hospitals. At our centre, a dedicated ambulatory care pathway, endorsed nationally, was established to treat and monitor patients with NO-myeloneuropathy in 2021 and refined through three audit cycles. We analysed the outcomes of patients on this pathway to better understand factors associated with non-engagement.
View Article and Find Full Text PDFLongitudinal follow-up and prognostic factors in nitrous oxide-induced neuropathy.
J Peripher Nerv Syst
June 2024
Reference Center for Neuromuscular Diseases and ALS, La Timone University Hospital, Aix-Marseille University, Marseille, France.
Background And Aim: Recreational use of nitrous oxide (NO) has been associated with the development of severe nitrous oxide-induced neuropathy (NOn). Follow-up of these patients poses challenges, and their clinical progression remains largely unknown. The identification of prognostic factors is made difficult by the lack of standardized longitudinal assessments in most studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!